Clitocine suppresses TNBC progression by boosting CCRL2 to block survival signals and neutrophil-driven inflammation
Qi Chen, Yanyun Ruan, Shuanshuan Liu, Hozeifa M. Hassan, Shaoyin Bao, Weiliang Liu, Jianguo Sun, Hongsheng Lu · 2026
Read Clitocine suppresses TNBC progression by boosting CCRL2 to block survival signals and neutrophil-driven inflammation by Qi Chen, Yanyun Ruan, Shuanshuan Liu, Hozeifa M. Hassan, Shaoyin Bao, Weiliang Liu, Jianguo Sun, Hongsheng Lu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471378.txt.
Description
Chen and co-authors studied clitocine, a natural compound, as a possible weapon against triple-negative breast cancer, an aggressive subtype that lacks the hormone targets most drugs aim at. Their 2026 laboratory and mouse study traced how the compound attacks tumor cells and reshapes the immune surroundings of the cancer. Such tumors make up about 15% to 20% of all breast cancers.
Clitocine slowed tumor cell growth and spread in two human cell lines and triggered cell death through the mitochondria, the cell's energy centers. It switched on CCRL2, a receptor gene that acts as a tumor suppressor, and patients with low CCRL2 levels tend to survive less long. In mice carrying 4T1 tumors, the compound shrank tumor growth without obvious whole-body toxicity, and it calmed neutrophil-driven inflammation inside the tumors.
Catalog record
| CREATOR | Qi Chen, Yanyun Ruan, Shuanshuan Liu, Hozeifa M. Hassan, Shaoyin Bao, Weiliang Liu, Jianguo Sun, Hongsheng Lu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |